Deferasirox for porphyria cutanea tarda: A pilot study

Archives of Dermatology

Volumn 148, Issue 8, 2012, Pages 898-901

  Pandya, Amit G ^a   Nezafati, Kaveh A ^a   Ashe Randolph, Mia ^a   Yalamanchili, Radha ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; FERRITIN; PORPHYRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; MALE; PILOT STUDY; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; PROSPECTIVE STUDY; TABLET FORMULATION; TERTIARY HEALTH CARE; UNITED STATES;

BENZOIC ACIDS; BLISTER; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; PORPHYRIA CUTANEA TARDA; PORPHYRINS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84865701058     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.807     Document Type: Article

References (9)

1. Bickers DR, Frank J. The porphyrias. In: Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ, eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York: McGraw-Hill; 2008:1228-1242.
2. Elder GH. Porphyria cutanea tarda. Semin Liver Dis. 1998;18(1):67-75.
3. Dereure O, Jumez N, Bessis D, Gallix B, Guillot B. Measurement of liver iron content by magnetic resonance imaging in 20 patients with overt porphyria cutanea tarda before phlebotomy therapy: a prospective study. Acta Derm Venereol. 2008; 88(4):341-345.
4. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462.
5. Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154(3):387-397.
6. Delforge M, Selleslag D, Triffet A, et al. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. Ann Hematol. 2011;90(6):655-666.
7. Rocchi E, Gibertini P, Cassanelli M, et al. Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion. Br J Dermatol. 1986;114(5):621-629.
8. Toyokuni S. Iron and carcinogenesis: from Fenton reaction to target genes. Redox Rep. 2002;7(4):189-197.
9. Novartis Pharmaceuticals. Deferasirox (Exjade) prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf. Accessed September 28, 2011.